2023 World Conference on Lung Cancer (Posters)-EP12.01. Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype

EP12.01. Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype - PDF(Abstract)

Back to course

Pdf Summary

This study examined the real-world outcomes of Asian patients with stage IV non-small cell lung cancer (NSCLC) who were treated with Osimertinib (Osi), a third-generation tyrosine kinase inhibitor (TKI), and stratified by EGFR subtype. The FLAURA trial previously demonstrated the efficacy of Osi compared to earlier generation TKIs, but subgroup analysis did not show the same survival benefit in Asian patients or in patients with the EGFR L858R mutation. <br /><br />The study included 109 Asian patients with EGFR exon 19 deletion (ex19del) or L858R mutations who received Osi as either first-line treatment or after an earlier generation TKI. The analysis revealed that the two-year overall survival (OS) was inferior in the first-line Osi group compared to the TKI-pretreated group. However, further subgroup analysis showed a significant difference in two-year OS only among patients with ex19del, not in those with L858R. <br /><br />The study suggests that treatment outcomes may differ between patients with ex19del and L858R mutations and should be considered differently when choosing first-line treatment. The results also indicate that Asian patients treated with first-line Osi had inferior outcomes compared to those treated with first- or second-generation TKIs and subsequently switched to Osi. The study calls for further investigation into alternative treatment options, such as combination therapy, particularly in the Asian population, where the FLAURA trial did not show any OS benefit from first-line Osi treatment over first-generation TKIs.

Asset Subtitle

Ying Liu

Meta Tag

Speaker Ying Liu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Asian patients

stage IV non-small cell lung cancer

Osimertinib

third-generation tyrosine kinase inhibitor

EGFR subtype

FLAURA trial

EGFR L858R mutation

first-line treatment

second-generation TKIs

survival benefit